Hematological Oncology

Published by: Wiley Blackwell  

People

  1. Kumar
    Kumar
  2. Zelenetz
    Zelenetz
  3. Noy
    Noy
  4. Hamlin
    Hamlin
  5. Moskowitz
    Moskowitz
  6. Horwitz
    Horwitz
  7. Palomba
    Palomba
  8. Yahalom
    Yahalom
  9. Dogan
    Dogan
  10. Schoder
    Schoder

Groups

  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (19)
  5. Survivorship Research (15)
  6. Executive Committee, Center for Hematologic Malignancies (11)
  7. Population Sciences Research Program (11)
  8. Epidemiology and Biostatistics (10)
  9. Biostatistics Service (8)
  10. Radiation Oncology, Department of (8)
Search Within
  1. "Anita Kumar"
Formats
  1. Meeting Abstract (19)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (19)
  5. Survivorship Research (15)
  6. Executive Committee, Center for Hematologic Malignancies (11)

More Groups

People
  1. Anita Kumar (19)
  2. David Straus (15)
  3. Andrew Zelenetz (14)
  4. Ariela Noy (13)
  5. Alison Moskowitz (12)
  6. Paul Hamlin (12)

More People

Years
  1. 2023 (3)
  2. 2021 (6)
  3. 2019 (3)
  4. 2017 (7)
Publishers
  1. Wiley Blackwell (19)

Results (19)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PET‐adapted therapy with nivolumab plus adriamycin, vinblastine, and dacarbazine for newly diagnosed stage III or IV Hodgkin Lymphoma
    Meeting Abstract

    Moskowitz, A.; Savage, K.; Feldman, T.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N‐AVD) as frontline therapy in older adults with Hodgkin lymphoma
    Meeting Abstract

    Torka, P.; Feldman, T.; Savage, K.; Ganesan, N.; Hancock, H.; Davey, T.; Perez, L.; Santarosa, A.; Subzwari, S.; Capadona, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Role of maintenance rituximab after first‐line bendamustine + rituximab or R‐CHOP in patients with mantle cell lymphoma from a large US real‐world cohort
    Meeting Abstract

    Wang, M.; Salles, G.; Kumar, A.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Martin, P.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Real‐world treatment patterns and outcomes of 3455 previously untreated mantle cell lymphoma patients in US routine clinical practice
    Meeting Abstract

    Kumar, A.; Martin, P.; Wang, M.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Salles, G.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Time to second line Bruton tyrosine kinase therapy and age at its initiation are strongly associated with subsequent overall survival in patients with first relapse of mantle cell lymphoma
    Meeting Abstract

    Villa, D.; Jiang, A.; Crosbie, N.; Rule, S.; McCulloch, R.; Visco, C.; Buege, M. J.; Kumar, A.; Bond, D.; Paludo, J.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The combination of duvelisib and romidepsin (DR) is highly active against relapsed/refractory peripheral T‐cell lymphoma with low rates of transaminitis: Final results
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Mehta‐Shah, N.; Jacobsen, E. D.; Khodadoust, M. S.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Myskowski, P.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save

    • Hematological Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 02780232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell
    Unknown (10991069) 10991069 Unknown